576 related articles for article (PubMed ID: 23343452)
21. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
22. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities.
Matos CS; de Souza Andrade A; Oliveira NS; Barros TF
Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1647-52. PubMed ID: 22278291
[TBL] [Abstract][Full Text] [Related]
23. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
24. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
26. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
[TBL] [Abstract][Full Text] [Related]
27. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
[TBL] [Abstract][Full Text] [Related]
28. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
[TBL] [Abstract][Full Text] [Related]
29. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.
Herkert PF; Hagen F; de Oliveira Salvador GL; Gomes RR; Ferreira MS; Vicente VA; Muro MD; Pinheiro RL; Meis JF; Queiroz-Telles F
Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1803-1810. PubMed ID: 27477855
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
32. Enzymatic characterisation of clinical isolates of Cryptococcus neoformans, Cryptococcus gattii and other environmental Cryptococcus spp.
Chan MY; Tay ST
Mycoses; 2010 Jan; 53(1):26-31. PubMed ID: 19389064
[TBL] [Abstract][Full Text] [Related]
33. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
35. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Espinel-Ingroff A; Chowdhary A; Cuenca-Estrella M; Fothergill A; Fuller J; Hagen F; Govender N; Guarro J; Johnson E; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; Trilles L; Kidd S; Turnidge J
Antimicrob Agents Chemother; 2012 Jun; 56(6):3107-13. PubMed ID: 22391546
[TBL] [Abstract][Full Text] [Related]
36. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.
Trilles L; Meyer W; Wanke B; Guarro J; Lazéra M
Med Mycol; 2012 Apr; 50(3):328-32. PubMed ID: 21859388
[TBL] [Abstract][Full Text] [Related]
37. Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.
Basso LR; Gast CE; Bruzual I; Wong B
J Antimicrob Chemother; 2015 May; 70(5):1396-407. PubMed ID: 25630649
[TBL] [Abstract][Full Text] [Related]
38. In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.
Chong HS; Dagg R; Malik R; Chen S; Carter D
J Clin Microbiol; 2010 Nov; 48(11):4115-20. PubMed ID: 20844209
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
40. [First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso].
Favalessa OC; Ribeiro LC; Tadano T; Fontes CJ; Dias FB; Coelho BP; Hahn RC
Rev Soc Bras Med Trop; 2009; 42(6):661-5. PubMed ID: 20209351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
